Skip to main content
Egyptian Liver Journal

Table 3 Tumor-related characteristics in HCC group (n = 28)

From: CTNNB1 polymorphism (rs121913407) in circulating tumor DNA (ctDNA) in Egyptian hepatocellular carcinoma patients

Parameters

N (%)

Number of focal lesions

1 (1–4)

Tumor size (cm)

4.8 (2.5–9.95)

Ascites

 No

12 (42.9%)

 Yes

16 (57.1%)

Encephalopathy

 No

26 (92.9%)

 Yes

2 (7.1%)

PVT

 No

16 (57.1%)

 Yes

12 (42.9%)

Metastatic liver lesions

 No

27 (96.4%)

 Yes

1 (3.6%)

Milan staging

 No

19 (67.9%)

 Yes

9 (32.1%)

UCSF staging

 No

25 (89.3%)

 Yes

3 (10.7%)

 CTP stage A

11 (39.3%)

 CTP stage B

11 (39.3%)

 CTP stage C

6 (21.4%)

 BCLC staging

0

 0

2 (7.1%)

 A

7 (25.0%)

 B

6 (21.4%)

 C

7 (25.0%)

 D

6 (21.4%)

  1. BCLC Barcelona clinic liver cancer, CTP Child-Turcotte-Pugh, HCC hepatocellular carcinoma, PVT portal vein thrombosis, UCSF Liver Center of the University of California, San Francisco. Data are presented as number (%)
Back to article page